Acrux (ASX: ACR), the Australia-based drug delivery company today reported that it will start a Phase 2 clinical trial in the USA following the recent acceptance of an Investigational New Drug Application (IND) for Testosterone MD-Lotion(R) by the US Food and Drug Administration (FDA).
